Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeOne MedicinesONC +2.94%77 Cash Ratio is 2.65 as of Mar. 2026, which is 38% below its 10-year median of 4.24. GuruFocus rates ONC with a GF Score™ of 77/100 and a GF Value™ of $372.61 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,384 Biotechnology companies, BeOne Medicines ranks worse than 53.25% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
BeOne Medicines Cash Ratio Related Terms
BeOne Medicines Cash Ratio Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BeOne Medicines's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cash Ratio distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (ONC) has a Cash Ratio of 2.65 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BeOne Medicines and its competitors. This is 38% below median its historical median of 4.24. Over the past decade, BeOne Medicines' Cash Ratio has ranged from 1.19 to 11.07. According to the industry distribution chart, BeOne Medicines ranks #737 out of 1384 companies in the Biotechnology industry, placing it in the top 53.3%.
Is BeOne Medicines' Cash Ratio too high?
BeOne Medicines' current Cash Ratio of 2.65 is 38% below median its 10-year median of 4.24. Over the past 10 years, this metric has ranged from a low of 1.19 to a high of 11.07. The Biotechnology industry median Cash Ratio is 2.93. BeOne Medicines' value of 2.65 is 9.6% below this industry median. Based on the distribution chart, BeOne Medicines ranks #737 out of 1384 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BeOne Medicines has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Cash Ratio compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #737 out of 1384 companies for Cash Ratio. This places BeOne Medicines in the lower half of its industry. The industry median Cash Ratio is 2.93. BeOne Medicines' value of 2.65 is 9.6% below this benchmark. Historically, BeOne Medicines' own Cash Ratio has ranged from 1.19 to 11.07 over the past decade. While the company's 10-year median is 4.24 vs. the industry median of 2.93, BeOne Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Cash Ratio of 2.65 is 9.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Cash Ratio is 2.65, which is 38% below median its own 10-year median of 4.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $372.61, compared to a current price of $323.01 — trading 13.3% below its estimated fair value. The current Cash Ratio is 2.65, which is 38% below median its 10-year median of 4.24 and 9.6% below the Biotechnology industry median of 2.93. BeOne Medicines' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Cash Ratio is 2.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $323.01 is trading 13.3% below its estimated GF Value™ of $372.61.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
Cash Ratio: 2.65 (38% below median its 10-year median of 4.24)
GF Value™: $372.61 vs. price of $323.01 (13.3% below fair value)
Industry Position: 9.6% below the Biotechnology median (#737 of 1384)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score
Get the complete analysis for ONC
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
